Gri­fols drops $1B on Ger­man hold­ing com­pa­ny in con­tin­ued plas­ma push

One Span­ish biotech is beef­ing up its plas­ma ther­a­py op­er­a­tions, and on Fri­day, it an­nounced that it’s do­ing so in a bil­lion-dol­lar deal.

Gri­fols is now the largest share­hold­er of Biotest, a com­pa­ny val­ued at more than $1.8 bil­lion. By team­ing up, the two will try to in­crease the num­ber of plas­ma ther­a­pies avail­able and in­crease pa­tient ac­cess around the world, Gri­fols said in a press re­lease.

The com­pa­ny did so by ac­quir­ing hold­ing com­pa­ny Tiancheng Phar­ma­ceu­ti­cal, the Ger­many-based own­er of near­ly 90% of Biotest shares, for near­ly $1.27 bil­lion. Gri­fols now owns near­ly 90% of Biotest vot­ing rights and al­most 45% of the to­tal share cap­i­tal of Biotest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER